Mortality and Recovery of Renal Function in Acute Kidney Injury Patients Treated with Prolonged Intermittent Hemodialysis Sessions Lasting 10 versus 6 Hours: Results of a Randomized Clinical Trial

Table 1

Clinical and laboratory characteristics of patients with AKI treated with PHD.

Parameters	General (n = 194)	G1 (n = 104)	G2 (n = 90)	p value
Age (in years)	60.8 ± 14.9	61.4 ± 14.4	60.2 ± 15.5	0.55
Males, n (%)	135 (69.5)	73 (70.1)	62 (68.8)	0.84
Weight	74.8 ± 22.5	74.1 ± 24	75.6 ± 20.8	0.63
Infectious focus n (%)
Pulmonary	80 (41.2)	43 (41.3)	37 (41.2)	0.97
Abdominal	69 (35.5)	31 (29.8)	38 (42.2)	0.07
Comorbidities, n (%)
(i) SAH	102 (52.5)	58 (55.7)	44 (48.8)	0.33
(ii) DM	53 (27.2)	29 (27.8)	24 (26.6)	0.84
(iii) CKD	19 (9.7)	12 (11.5)	7 (7.7)	0.37
ATN-ISS	0.77 ± 0.1	0.76 ± 0.1	0.77 ± 0.2	0.87
SOFA	14.2 ± 2.9	14.1 ± 3	14,4 ± 2,9	0.47
Pre-dialysis FB (l)	3.36 ± 1.8	3.27 ± 1.9	3.47 ± 1.7	0.47
Ur (mg/dl)	155.3 ± 105.7	158.6 ± 59.5	151.6 ± 141.2	0.64
Cr (mg/dl)	3.7 ± 1.5	3.7 ± 1.4	3.6 ± 1.7	0.64
K (mEq/L)	4.7 ± 1	4.7 ± 1	4.8 ± 1	0.48
Bic (mEq/L)	19.1 ± 4.6	18.8 ± 4.7	19.5 ± 4.6	0.39
Mechanical Ventilation	182 (93.8)	98 (94.2)	84 (93.3)	0.96
Initial vasoactive drug dose	0.55 ± 0.18	0.55 ± 0.17	0.56 ± 0.19	0.97
Final vasoactive drug dose	0.69 ± 0.19	0.69 ± 0.16	0.70 ± 0.20	0.91

Values are presented in frequency, mean values and standard deviation, median, and proportions.
AKI: acute renal injury, PHD: prolonged hemodialysis, SAH: systemic arterial hypertension, DM: diabetes mellitus, CKD: chronic kidney disease, ATN-ISS: acute tubular necrosis individual severity score, SOFA: sequential organ failure assessment score, FB: fluid balance, Ur: urea, Cr: creatinine, K: potassium, Bic: bicarbonate, and UF: ultrafiltration.